GLENMARK PHARMACEUTICALS LTD.

GLENMARK PHARMACEUTICALS LTD. - Updates

Download	< Back
21 Feb 2017
Glenmark Pharmaceuticals Ltd vide its letter dated February 20, 2017 has informed BSE about the following :<BR><BR>"We have received today a query from the media regarding Glenmark receiving the observations on its Ankleshwar Plant in Gujarat pursuant to the USFDA Audit.<BR><BR>Our response which will be sent to the media agency is given below:<BR><BR>"The API plant at Ankleshwar, India was inspected by the USFDA in December 2016. We received four observations from the FDA via the Form 483. We responded to the observations in January 2017. At this point in time, we have no outstanding items with the USFDA regarding this plant. The Form 483 is an integral part of the inspection process which is used to communicate inspection observations by the USFDA after it audits the manufacturing facility.""
View all announcements for GLENMARK PHARMACEUTICALS LTD.	Source: BSE India

Stocks	Mutual Funds		Investment tracking
A-Z Gainers - Daily \| Weekly \| Monthly Losers - Daily \| Weekly \| Monthly Group-wise listing IPO \| Top IPOs Recent IPOs \| IPO News Similar Price band Most traded - By volumes Top 100 - By market capitalisation Latest Company Results Management Speaks Market News	Top 25 schemes High-risk, High-returns Medium-risk, Medium-returns Low-risk, Low-returns Gilt Funds Funds of Funds Special Funds Liquid Funds Dynamic Asset Allocation NFOs MF Selector	Equity - ELSS Equity - Index Funds Equity - Sector Funds Equity - Balance Fund Equity - Diversified Fund MF News Budget 2024	My Portfolio My Watch List If You Had Invested... Global Indicators Forex Converter Market Indices Sectoral Indices World Indices Market Astrology Advertise with us